cancel

Privacy Policy

Your privacy is important to HealthWorks Pvt. Ltd. This privacy statement provides information about the personal information that HealthWorks Pvt. Ltd collects, and the ways in which HealthWorks Pvt. Ltd. uses that personal information

Personal information collection
HealthWorks Pvt. Ltd. may collect and use the following kinds of personal information:
  • information about your use of this website (including [Helping you in your lifestyle disorder, guiding you to the right consultant and to help you better you
  • information that you provide using for the purpose of registering with the website (including [Name, Email address, Telephone number, referral contact and city
  • any other information that you send to HealthWorks Pvt. Ltd.

Using personal information
HealthWorks Pvt. Ltd. may use your personal information to:
  • Administer this website
  • Personalize the website for you
  • Enable your access to and use of the website services
  • Publish information about you on the website
  • Supply to you services that you purchase
  • Send to you statements and invoices
  • Send you marketing communications

Where HealthWorks Pvt. Ltd. discloses your personal information to its agents or sub-contractors for these purposes, the agent or sub-contractor in question will be obligated to use that personal information in accordance with the terms of this privacy statement.

In addition to the disclosures reasonably necessary for the purposes identified elsewhere above, HealthWorks Pvt. Ltd. may disclose your personal information to the extent that it is required to do so by law, in connection with any legal proceedings or prospective legal proceedings, and in order to establish, exercise or defend its legal rights.

Securing your data
HealthWorks Pvt. Ltd. will take reasonable technical and organisational precautions to prevent the loss, misuse or alteration of your personal information.
HealthWorks Pvt. Ltd. will store all the personal information you provide [on its secure servers.
Information relating to electronic transactions entered into via this website will be protected by encryption technology.

Cross-border data transfers
Information that HealthWorks Pvt. Ltd. collects may be stored and processed in and transferred between any of the countries in which HealthWorks Pvt. Ltd. operates to enable the use of the information in accordance with this privacy policy.

In addition, personal information that you submit for publication on the website will be published on the internet and may be available around the world.

You agree to such cross-border transfers of personal information.

Updating this statement
HealthWorks Pvt. Ltd. may update this privacy policy by posting a new version on this website.
You should check this page occasionally to ensure you are familiar with any changes.

Other websites
This website contains links to other websites.
HealthWorks Pvt. Ltd.is not responsible for the privacy policies or practices of any third party.

Contact HealthWorks Pvt. Ltd.
If you have any questions about this privacy policy or HealthWorks Pvt. Ltd. treatment of your personal information, please write:
  • by email to info@myhealthworks.in

Cardiomyopathy and COQ10

Abstract
The tissue levels of coenzyme Q10 (CoQ10) in endomyocardial biopsy samples and blood from 43 patients with cardiomyopathy were determined by steps of extraction, purification, and HPLC. The biopsy samples were obtained from the patients after a routine heart catheterization. Six patients were of class I, 18 of class II, 11 of class III, and 8 of class IV (classified according to guidelines of the New York Heart Association). True control biopsies of healthy hearts are not available for ethical reasons, but the data of the four classes by severity of disorder may be justifiably compared. Patients of class IV had lower (P less than 0.01) levels of CoQ10 than those of class I. Patients of classes III and IV had a lower (P less than 0.0001) level than those of classes I and II. Biopsy samples were obtained from five patients after treatment with CoQ10 for 2-8 months. The increases of CoQ10 levels ranged from 20% to 85%; the mean value was higher (P less than 0.02) than before treatment. Blood deficiencies also increase with severity of disorder, but not as markedly as for the biopsies. These data reveal a myocardial deficiency of CoQ10, which is higher with increasing severity of disorder and is reduced by therapy. This biochemistry correlates with the effective treatment of cardiomyopathy with CoQ10.

During 1982-86, 43/137 patients with a cardiomyopathy, Classes II, III and IV, had ejection fractions (EF) below 40%, and a mean EF of 25.1 +/- 10.3%. During treatment of these 43 patients with a coenzymeQ10 (CoQ10), EF increased to 41.6 +/- 14.3% (p less than 0.001) over a mean period of 3 months (range, 2-4 months). At four subsequent periods up to 36 months. EF ranged from 43.1 +/- 13.3 to 49.7 +/- 6.4% (each period, p less than 0.001). The mean CoQ10 control blood level was 0.85 +/- 0.26 micrograms/ml which increased on treatment to 1.7 to 2.3 micrograms/ml for five periods up to 36 months (each period, p less than 0.001). The survival rates for all 137 patients treated with CoQ10 and for the 43 patients with EF below 40% were both about 75%/46 months. These two survival rates were comparable between 24 and 46 months, which is of extraordinary significance and importance when compared to survival of about 25%/36 months for 182 patients with EF below 46% on conventional therapy without CoQ10. The improved cardiac function and pronounced increase of survival show that therapy with CoQ10 is remarkably beneficial due to correction of CoQ10 deficiency in mechanisms of bioenergetics.

PubMed ID3856239 Publication HistoryPublished on February 1, 1985